ReviewAntiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options
Introduction
For a decade, therapeutic options against HIV-1 infection were limited, consisting only of a single class of drugs, the nucleoside analogue reverse transcriptase inhibitors (nRTIs). The impact of these agents on plasma HIV-1 RNA levels was modest and the development of serious immunodeficiency inevitable. This unsatisfactory situation was dramatically changed with the introduction of inhibitors of the HIV-1 protease. These agents inhibit the cleavage of gag–pol polyproteins. The administration of two nRTIs and a protease inhibitor (PI) in combination resulted in sustained reductions of plasma HIV-1 RNA levels and larger increases of CD4+ T lymphocytes than had been seen with nucleoside analogue therapy [[1], [2]]. Consequently, triple combination therapy using any three drugs was termed highly active antiretroviral therapy (HAART). The widespread use of HAART was associated with an impressive decline in the morbidity and mortality of HIV-1 infected subjects [3], [4], [5]. In the past two years, new antiretroviral drugs have become available and different treatment strategies have been investigated, increasing the number of possible treatment options. In this review, we focus on these new antiretroviral therapeutic options.
Section snippets
Antiviral and immunological effects of HAART
Antiretroviral therapy aims to reduce the viral burden and ultimately, to eradicate HIV-1 infection. Typically, plasma HIV-1 RNA declines in a biphasic pattern in subjects on HAART (Fig. 1), reaching undetectable levels in 50–90% of individuals. The virological response strongly depends on the previous drug history, presumably reflecting the extent of any prior selection of drug-resistant mutants as a result of suboptimal therapy.
Recent studies provided evidence that replication competent virus
Treatment strategies
Currently available classes of antiretroviral drugs include nucleoside reverse transcriptase inhibitors (nRTIs), PIs and non-nucleoside reverse transcriptase inhibitors (nnRTIs) (Table 1). Detailed recommendations on the use associated with these drugs have been provided by several international panels of specialists [24], [25], [26].
Nucleoside analogue reverse transcriptase inhibitors
Mono- or dual regimens of nRTI are now considered to be obsolete, because they usually only lead to transient reductions of plasma HIV-1 RNA and rapid emergence of drug-resistant virus. Several studies have shown that the antiviral response to a combination of two nRTIs, or one protease inhibitor and one nRTI is inferior to that of a regimen consisting of one protease inhibitor and two nRTIs [[1], [2], [27], [28], [29]]. Similarly, sequential combination therapy, starting with one or two drugs
Protease inhibitors
Available protease inhibitors include soft-gel saquinavir, ritonavir, indinavir, nelfinavir and amprenavir. The previous hard-gel formulation of saquinavir showed a poor bioavailability of 4% and should only be used in combination with ritonavir, which inhibits the metabolism of saquinavir to compensate for the poor bioavailability, increasing concentrations up to 20-fold. Clinical data on amprenavir are still very limited. A new protease inhibitor lopinavir (ABT 378) is currently under
Non-nucleoside analogue reverse transcriptase inhibitors
An alternative treatment option is the combination of two nRTIs with an nnRTI such as efavirenz, nevirapine or delavirdine. Efavirenz in combination with zidovudine and lamivudine showed a profound antiviral response in antiretroviral naı̈ve patients, similar to the response seen with indinavir-containing triple therapy [42]. At week 48 of treatment, 64% of subjects treated with the efavirenz-containing triple therapy and 43% of those treated with the indinavir-containing triple therapy had
Initiation of HAART
In view of the rapid evolution of viral diversity and the continuous dissemination of HIV-1 to all body compartments, early aggressive therapy has been promulgated. Certain authorities recommend commencement of therapy during primary HIV-1 infection. An early initiation of HAART leads to sustained antiviral responses and a rapid recovery of the immune system [[48•], [49•]]. On the other hand, it has to be considered that is difficult to maintain good adherence to the drug regimen over many
Salvage regimens
The chance of a good virological response to a second or third drug regimen is considerably lower than to the first therapy, suggesting either that the initial drug regimen should be as potent as possible, providing a durable response, or that the most potent classes of drugs should be saved for later. The selection of salvage regimens may be improved by drug resistance tests. In one study, the reduction of plasma HIV-1 RNA levels was larger and the proportion of subjects with plasma HIV-1 RNA
Induction/maintenance strategy
Three induction/maintenance studies have been published [[55•], [56], [57]]. Induction/maintenance studies involve the use of a potent therapy to induce viral remission (three to four drugs), followed by a less intense therapy (two drugs) to maintain the patient in remission. In two of the studies, triple combinations were used for induction therapy, consisting of indinavir and two nRTIs. In the third study, induction therapy consisted of saquinavir, nelfinavir and two nRTIs. The drugs used in
Limitations of HAART
Drug resistance occurs frequently and is responsible for a large proportion of treatment failures. Poor adherence to the drug regimen has been shown to be an important co-factor for treatment failure and might facilitate the selection of drug resistant HIV-1. Patient counselling, therefore, appears to be crucial to optimise antiretroviral therapy.
Protease inhibitors and nnRTIs are both metabolized by CYP450 enzymes, resulting in complex pharmacokinetic interactions that alter the metabolism of
Conclusions and future trends
The failure to eradicate HIV-1 infection indicates that long-term or even life-long antiretroviral therapy is required. This observation emphasises the need for a well tolerated drug regimen with simple dosage schedules that provides a durable therapeutic response. Current treatment guidelines recommending combinations of protease inhibitors and nRTIs are based on the extensive experience with these therapies. However, recent studies provided evidence that the protease inhibitor may be
Acknowledgements
The National Centre in HIV Epidemiology and Clinical Research is funded by the Commonwealth Department of Health and Aged Care, through the Australian National Council on AIDS and Related Diseases (ANCARD). We thank John Zaunders, Mark Bloch and Don Smith for carefully reading the manuscript.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
of special interest
of outstanding interest
References (63)
- et al.
Changing patterns of mortality across Europe in patients infected with HIV-1
Lancet
(1998) - et al.
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
Lancet
(1998) - et al.
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study
Lancet
(1998) - et al.
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group
Lancet
(1999) - et al.
Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
Lancet
(1999) - et al.
1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee
Lancet
(1998) - et al.
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group
Lancet
(1998) - et al.
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
Lancet
(1999) - et al.
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
Lancet
(1998) - et al.
Natural history, diagnosis and prediction of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus
Lancet
(1999)
Severe premature coronary artery disease with protease inhibitors
Lancet
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
JAMA
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
N Engl J Med
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
N Engl J Med
Estimating the population impact in Australia of improved antiretroviral treatment for HIV infections
AIDS
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Science
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines
J Exp Med
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Science
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
N Engl J Med
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Nat Med
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
N Engl J Med
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
Nat Med
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
AIDS
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
J Infect Dis
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
Science
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation
Nat Med
Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
Nat Med
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
Science
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
N Engl J Med
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel
JAMA
Cited by (53)
Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries
2015, Antiviral ResearchCitation Excerpt :Although antiretroviral nucleoside derivatives are largely used against HIV infection for their efficacy at the peripheral level, the total eradication of this virus from the body is currently difficult to achieve. Indeed, antiretroviral drugs are unable to reach the CNS (Kaufmann and Cooper, 2000; Strazielle et al., 2003); in contrast, the CNS is easily reached by HIV through infected monocytes (Davis et al., 1992; Gray et al., 1996) that differentiate into macrophages and microglia in the brain (Rausch and Stover, 2001). Therefore, the CNS and those macrophages constitute sanctuaries for HIV, where drug resistance is induced and from which the periphery can be re-infected (Cunningham et al., 2000; Kolson and Gonzalez-Scarano, 2000).
Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors
2012, Bioorganic and Medicinal Chemistry LettersSynthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus
2010, Bioorganic and Medicinal Chemistry LettersSynthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains
2007, European Journal of Medicinal ChemistryCitation Excerpt :Multi-drug therapy against the human immunodeficiency virus (HIV), known as highly active antiretroviral therapy (HAART) [1,2], has drastically reduced the morbidity and mortality of HIV-infected patients during the last decade and slowed down the progression of acquired immunodeficiency syndrome (AIDS).
Determination of antiretroviral agents in human serum by capillary electrophoresis
2005, Journal of Chromatography AHCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen
2005, Journal of Molecular Biology